Pfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood Disorders
Portfolio Pulse from Vandana Singh
Pfizer Inc has decided to terminate its License and Collaboration Agreement with Syros Pharmaceuticals Inc for the development of therapies for sickle cell disease and beta-thalassemia. The termination will be effective from October 16, 2023. This ends Pfizer's three-year-long collaboration with Global Blood Therapeutics, which it acquired last year. Syros plans to find a new out-licensing partner for its sickle cell disease program.
July 24, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pfizer's termination of its agreement with Syros could potentially slow down its progress in developing therapies for sickle cell disease and beta-thalassemia.
The termination of the agreement with Syros could potentially slow down Pfizer's progress in the development of therapies for sickle cell disease and beta-thalassemia. This could impact Pfizer's future revenues and growth in this therapeutic area.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Syros Pharmaceuticals will need to find a new out-licensing partner for its sickle cell disease program following the termination of its agreement with Pfizer.
The termination of the agreement with Pfizer means that Syros will need to find a new out-licensing partner for its sickle cell disease program. This could potentially delay the development and commercialization of its therapies, impacting its future revenues and growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100